Compare CPAC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | URGN |
|---|---|---|
| Founded | 1949 | 2004 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 2.2B |
| IPO Year | 2003 | 2016 |
| Metric | CPAC | URGN |
|---|---|---|
| Price | $12.17 | $41.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $12.90 | ★ $29.29 |
| AVG Volume (30 Days) | 43.1K | ★ 597.6K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $4.49 | $129.09 |
| Revenue Next Year | N/A | $70.96 |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $15.86 |
| 52 Week High | $12.74 | $50.81 |
| Indicator | CPAC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 41.02 |
| Support Level | $12.10 | $18.25 |
| Resistance Level | $12.38 | $44.63 |
| Average True Range (ATR) | 0.19 | 2.01 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 15.62 | 23.16 |
Cementos Pacasmayo SAA is a Peruvian cement company, and only cement manufacturer serving in the northern region of Peru. It produce, distribute and sell cement and cement-related materials, such as precast products and ready-mix concrete. Its products are mainly used in construction, which has been one of the fastest growing segments of the Peruvian economy in recent years. It also produce and sell quicklime for use in mining operations. It also provide transportation services. It has three operating segments cement, concrete, mortar, pavement and precast; quicklime; and sales of construction supplies. The majority of profit comes from Cement segment. Peru's cement production is into three regions northern region, central region, including Lima's metropolitan area, and southern region.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.